Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma
American Journal of Ophthalmology
May 2026
Vaisman D.
Strategies for extending the half-life of biotherapeutics: successes and complications
Expert Opinion on Biological Therapy
2025
Binder U.
Open Access
A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
Current Issues in Molecular Biology
October 2023
Medina C.
Open Access
Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C
Hepatitis Monthly
29 September 2015
Pouresmaeeli M.
Open Access
Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C
Cochrane Database of Systematic Reviews
28 February 2014
Hauser G.
All Open Access, Green
Statin efficacy in the treatment of hepatitis C genotype I
Journal of Research in Medical Sciences
2014
Shavakhi A.
Mysterious linkages between hepatitis C virus genotypes, interleukin-28B genotypes and viral clearance- a meta-analysis
Hepatitis Monthly
2014
Aalaei-Andabili S.H.
Open Access
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
Cost Effectiveness and Resource Allocation
8 October 2013
Barros F.M.R.
Open Access
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin
Indian Journal of Gastroenterology
September 2013
Lashin A.H.
Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in Iran
Hepatitis Monthly
31 August 2013
Mehrazmay A.
Open Access
Efficacy and tolerability of peginterferon α -2a and peginterferon α -2b, both plus ribavirin, for chronic hepatitis C: A meta-analysis of randomized controlled trials
Gastroenterology Research and Practice
2013
Yang Z.
Open Access
Efficacy and safety of pegylated interferon Alfa-2a or Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: A systematic review and meta-analysis
Clinical Infectious Diseases
1 April 2013
Druyts E.
The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: A single centre egyptian study
Hepatitis Monthly
May 2013
El Raziky M.
Open Access
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: An indirect comparison meta-analysis
Therapeutics and Clinical Risk Management
2012
Cooper C.L.
Open Access
Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: A meta-analysis
Clinical and Experimental Gastroenterology
2012
Druyts E.
Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts
BMC Gastroenterology
18 January 2012
Lin K.H.
Open Access
High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C
Iranian Red Crescent Medical Journal
2012
Moghaddam M.A.
Herbal medicine and liver disease, for any conclusion we need to do more studies
Journal of Research in Medical Sciences
July 2011
Alavian S.M.
Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials
Hepatology
December 2010
Kershenobich D.
Open Access
Peginterferon α-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: A single-centre study of 367 cases
Liver International
September 2010
Alavian S.M.
Type of pegylated interferon matters: Another milestone in the treatment of hepatitis C virus infection
Hepatitis Monthly
2010
Singal A.K.
Interferon-based therapy for chronic hepatitis C: Current and future perspectives
Hepatitis Monthly
2010
de Re V.
Interferon: A sharp sword to overcome HCV or HBV-related liver diseases?
Hepatitis Monthly
2010
Jia W.D.
Distribution of hepatitis C virus genotypes in Iranian patients with congenital bleeding disorders
Iranian Red Crescent Medical Journal
November 2010
Keshvari M.